FMI
VRTX icon

F/M Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

F/M Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Sell
875
-446
-34% -$198K 0.02% 275
2026
Q1 		$590K Sell
1,321
-8,163
-86% -$3.81M 0.04% 219
2025
Q4 		$4.3M Sell
9,484
-280
-3% -$121K 0.16% 160
2025
Q3 		$3.82M Sell
9,764
-19,534
-67% -$8.16M 0.15% 163
2025
Q2 		$13M Buy
29,298
+5
+0% +$2.3K 0.47% 39
2025
Q1 		$14.2M Sell
29,293
-1,622
-5% -$756K 0.57% 36
2024
Q4 		$12.4M Sell
30,915
-11,548
-27% -$5.35M 0.46% 42
2024
Q3 		$19.7M Sell
42,463
-4,731
-10% -$2.27M 0.62% 29
2024
Q2 		$22.1M Buy
47,194
+43,093
+1,051% +$18.7M 0.8% 22
2024
Q1 		$1.71M Sell
4,101
-28
-0.7% -$11.8K 1.16% 25
2023
Q4 		$1.68M Buy
+4,129
New +$1.53M 0.95% 35
2022
Q2 		– Sell
-10,076
Closed -$2.63M – 95
2022
Q1 		$2.63M Sell
10,076
-9
-0.1% -$2.14K 2.12% 16
2021
Q4 		$2.21M Buy
+10,085
New +$1.96M 1.62% 24

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

F/M Investments's VRTX Position: Q2 2026 in Review

F/M Investments reduced its Vertex Pharmaceuticals (VRTX) stake by 34% in Q2 2026, selling an estimated $198K and leaving 875 shares worth $435K. The position accounts for 0.02% of the portfolio, ranked #275.

F/M Investments first reported a position in VRTX in Q4 2021 and has held it in 13 quarters since. The position peaked at $22.1M in Q2 2024. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • F/M Investments held 875 shares of Vertex Pharmaceuticals worth $435K as of Q2 2026.
  • F/M Investments sold 446 Vertex Pharmaceuticals shares in Q2 2026, an estimated $198K.
  • Vertex Pharmaceuticals made up 0.02% of F/M Investments's portfolio in Q2 2026, its #275 holding.
  • F/M Investments first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • F/M Investments's Vertex Pharmaceuticals position peaked at $22.1M in Q2 2024.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.